{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:53:49Z","timestamp":1790276029948,"version":"4.1.0"},"reference-count":57,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2017,6,5]],"date-time":"2017-06-05T00:00:00Z","timestamp":1496620800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007052","name":"Memorial Sloan-Kettering Cancer Center","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0178593","type":"journal-article","created":{"date-parts":[[2017,6,5]],"date-time":"2017-06-05T17:39:19Z","timestamp":1496684359000},"page":"e0178593","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":49,"title":["A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors"],"prefix":"10.1371","volume":"12","author":[{"given":"Oren J.","family":"Becher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5774-3161","authenticated-orcid":true,"given":"Nathan E.","family":"Millard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakeel","family":"Modak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian H.","family":"Kushner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Haque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Spasojevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya M.","family":"Trippett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen W.","family":"Gilheeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Khakoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Lyden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"De Braganca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill M.","family":"Kolesar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason T.","family":"Huse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Kong V.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira J.","family":"Dunkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,6,5]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/nrd1902","article-title":"Exploiting the PI3K\/AKT pathway for cancer drug discovery","volume":"4","author":"BT Hennessy","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1535-6108(03)00248-4","article-title":"Targeting the PI3K-Akt pathway in human cancer: rationale and promise","volume":"4","author":"J Luo","year":"2003","journal-title":"Cancer Cell"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1073\/pnas.96.8.4240","article-title":"New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase\/AKT pathway","volume":"96","author":"LC Cantley","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nature04869","article-title":"Ras, PI(3)K and mTOR signalling controls tumour cell growth","volume":"441","author":"RJ Shaw","year":"2006","journal-title":"Nature"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11060-010-0297-3","article-title":"Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children&apos;s Oncology Group","volume":"99","author":"IF Pollack","year":"2010","journal-title":"J Neurooncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/neuonc\/nos140","article-title":"PTEN promoter methylation and activation of the PI3K\/Akt\/mTOR pathway in pediatric gliomas and influence on clinical outcome","volume":"14","author":"S Mueller","year":"2012","journal-title":"Neuro Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1158\/1541-7786.MCR-09-0069","article-title":"The alkylphospholipid perifosine induces apoptosis and p21-mediated cell cycle arrest in medulloblastoma","volume":"7","author":"A Kumar","year":"2009","journal-title":"Mol Cancer Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1158\/0008-5472.CAN-06-2201","article-title":"Activation of Akt predicts poor outcome in neuroblastoma","volume":"67","author":"D Opel","year":"2007","journal-title":"Cancer Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1158\/0008-5472.CAN-06-1344","article-title":"Phosphoprotein pathway mapping: Akt\/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival","volume":"67","author":"EF Petricoin 3rd","year":"2007","journal-title":"Cancer Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"e10849","DOI":"10.1371\/journal.pone.0010849","article-title":"Heterozygosity for Pten promotes tumorigenesis in a mouse model of medulloblastoma","volume":"5","author":"RC Castellino","year":"2010","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1158\/1078-0432.CCR-07-1616","article-title":"Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas","volume":"14","author":"HK Thorarinsdottir","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/35077225","article-title":"Oncogenic kinase signalling","volume":"411","author":"P Blume-Jensen","year":"2001","journal-title":"Nature"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0092-8674(02)01083-8","article-title":"PKB binding proteins. Getting in on the Akt","volume":"111","author":"DP Brazil","year":"2002","journal-title":"Cell"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrg1879","article-title":"The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism","volume":"7","author":"JA Engelman","year":"2006","journal-title":"Nat Rev Genet"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: navigating downstream","volume":"129","author":"BD Manning","year":"2007","journal-title":"Cell"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ccr.2010.10.031","article-title":"AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity","volume":"19","author":"S Chandarlapaty","year":"2011","journal-title":"Cancer Cell"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/1535-7163.MCT-13-0639","article-title":"Picking the point of inhibition: a comparative review of PI3K\/AKT\/mTOR pathway inhibitors","volume":"13","author":"R Dienstmann","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3109\/07853890.2014.912836","article-title":"PI3K\/AKT signaling pathway and cancer: an updated review","volume":"46","author":"M Martini","year":"2014","journal-title":"Ann Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"7429","DOI":"10.1158\/0008-5472.CAN-05-1042","article-title":"Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo","volume":"65","author":"H Momota","year":"2005","journal-title":"Cancer Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1101\/gad.1627008","article-title":"PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo","volume":"22","author":"D Hambardzumyan","year":"2008","journal-title":"Genes Dev"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/jnci\/djq125","article-title":"In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine","volume":"102","author":"Z Li","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.bbalip.2012.10.008","article-title":"Anticancer mechanisms and clinical application of alkylphospholipids","volume":"1831","author":"WJ van Blitterswijk","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2174\/1871520614666140309225912","article-title":"Current view on the mechanism of action of perifosine in cancer","volume":"14","author":"J Fensterle","year":"2014","journal-title":"Anticancer Agents Med Chem"},{"key":"ref24","first-page":"1093","article-title":"Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation","volume":"2","author":"SB Kondapaka","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"21816","DOI":"10.18632\/oncotarget.5200","article-title":"Perifosine as a potential novel anti-telomerase therapy","volume":"6","author":"B Holohan","year":"2015","journal-title":"Oncotarget"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-8722-7-1","article-title":"Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin\/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors","volume":"7","author":"LR Molife","year":"2014","journal-title":"J Hematol Oncol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1200\/JCO.2011.36.1980","article-title":"Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer","volume":"29","author":"JC Bendell","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1200\/JCO.2010.33.9788","article-title":"Perifosine plus bortezomib and dexamethasone in patients with relapsed\/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I\/II trial","volume":"29","author":"PG Richardson","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3109\/10428194.2013.824080","article-title":"Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies","volume":"55","author":"DR Friedman","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10637-005-1436-0","article-title":"Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid","volume":"23","author":"SR Vink","year":"2005","journal-title":"Invest New Drugs"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/S0959-8049(02)00127-2","article-title":"Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours","volume":"38","author":"M Crul","year":"2002","journal-title":"Eur J Cancer"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1158\/1078-0432.CCR-03-0406","article-title":"A phase I trial of perifosine (NSC 639966) on a loading dose\/maintenance dose schedule in patients with advanced cancer","volume":"10","author":"L Van Ummersen","year":"2004","journal-title":"Clin Cancer Res"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.ejca.2009.12.028","article-title":"First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours","volume":"46","author":"C Unger","year":"2010","journal-title":"Eur J Cancer"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0378-4347(01)00231-6","article-title":"Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometry","volume":"759","author":"EW Woo","year":"2001","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"P Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/JCO.1993.11.8.1466","article-title":"Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment","volume":"11","author":"GM Brodeur","year":"1993","journal-title":"J Clin Oncol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00280-014-2569-7","article-title":"A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms","volume":"74","author":"WD Figg","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"10059","DOI":"10.1200\/jco.2007.25.18_suppl.10059","article-title":"Perifosine (P) as an active agent in the treatment of patients with advanced sarcoma [abstract]","volume":"25","author":"R Birch","year":"2007","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s13277-015-3740-4","article-title":"Preclinical evaluation of perifosine as a potential promising rhabdomyosarcoma agent","volume":"37","author":"K Shen","year":"2016","journal-title":"Tumor Biol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1200\/JCO.2011.35.5263","article-title":"First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors","volume":"29","author":"TA Yap","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/pbc.25023","article-title":"A phase I trial of MK-2206 in children with refractory malignancies: a Children&apos;s Oncology Group study","volume":"61","author":"M Fouladi","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"5816","DOI":"10.1158\/1078-0432.CCR-12-1141","article-title":"Biomarkers of response to Akt inhibitor MK-2206 in breast cancer","volume":"18","author":"T Sangai","year":"2012","journal-title":"Clin Cancer Res"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1158\/1535-7163.MCT-11-0824-T","article-title":"Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background","volume":"11","author":"BR Davies","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1158\/1078-0432.CCR-12-3072","article-title":"Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models","volume":"19","author":"J Lin","year":"2013","journal-title":"Clin Cancer Res"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"LBA3501","DOI":"10.1200\/jco.2012.30.18_suppl.lba3501","article-title":"Results of the X-PECT study: A phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC) [abstract]","volume":"30","author":"JC Bendell","year":"2012","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"ref46","unstructured":"Valli\u00e8res GB, Burroughs P. Aeterna Zentaris to Discontinue Phase 3 Trial in Multiple Myeloma with Perifosine Following Data Safety Monitoring Board Recommendation 2013 [cited 2016 February 22]; <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.aezsinc.com\/en\/page.php?p=60&q=550\" xlink:type=\"simple\">http:\/\/www.aezsinc.com\/en\/page.php?p=60&amp;q=550<\/ext-link>"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0014-5793(03)00058-9","article-title":"Regulation of telomerase activity and anti-apoptotic function by protein-protein interaction and phosphorylation","volume":"563","author":"J Haendeler","year":"2003","journal-title":"FEBS Lett"},{"key":"ref48","first-page":"2457","article-title":"Alkyl-lysophospholipids activate the SAPK\/JNK pathway and enhance radiation-induced apoptosis","volume":"59","author":"GA Ruiter","year":"1999","journal-title":"Cancer Res"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"8967","DOI":"10.1158\/0008-5472.CAN-09-2190","article-title":"Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components of the mTOR axis and induces autophagy","volume":"69","author":"L Fu","year":"2009","journal-title":"Cancer Res"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/1479-5876-11-241","article-title":"The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere","volume":"11","author":"J Li","year":"2013","journal-title":"J Transl Med"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.18632\/oncotarget.3260","article-title":"Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia","volume":"6","author":"A Cani","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"ref52","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/ijc.30440","article-title":"A phase I\/Ib trial targeting the PI3K\/AKT pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma","volume":"140","author":"BH Kushner","year":"2017","journal-title":"Int J Cancer"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00280-015-2711-1","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model","volume":"75","author":"DE Cole","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF02968569","article-title":"Blood-brain barrier interfaces and brain tumors","volume":"29","author":"SW Lee","year":"2006","journal-title":"Arch Pharm Res"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1038\/ncomms5196","article-title":"Disruption of astrocyte-vascular coupling and the blood-brain barrier by invading glioma cells","volume":"5","author":"S Watkins","year":"2014","journal-title":"Nat Commun"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s11060-011-0564-y","article-title":"Tissue concentration of systemically administered antineoplastic agents in human brain tumors","volume":"104","author":"MW Pitz","year":"2011","journal-title":"J Neurooncol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00381-015-2640-7","article-title":"Toxicity evaluation of convection-enhanced delivery of small-molecule kinase inhibitors in naive mouse brainstem","volume":"31","author":"Z Zhou","year":"2015","journal-title":"Childs Nerv Syst"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0178593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T15:40:40Z","timestamp":1719243640000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0178593"}},"subtitle":[],"editor":[{"given":"Amir","family":"Abdollahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,6,5]]},"references-count":57,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,6,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0178593","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,5]]}}}